We Work to Cure Cancer

By combining our cutting edge prediction technology with cancer drugs, we offer precision treatment for patients with cancer. Our patients have better chances of living longer and ultimately survive.
Oncology Venture DRP Method

Tracking cancers with high precision

It is well known that various cancer types require completely different kinds of treatments. Less known is that each individual patient is unique in terms of which treatment works best. This is partly due to the fact that all humans are unique. An even more important explanation is that on a cellular level, there are several millions of possible causes for tumor development. Oncology Venture tracks the individual cancer to identify its unique characteristics.

Matching drugs with patients

As a consequence of the complexity of cancers, it is a significant challenge to match the right treatment to the right patient, both in clinical practice and in drug development. This leads to lower efficacy rates than both patients and doctors could wish for.

Treatments with better efficacy

But cancer is no longer an enigma. And Oncology Venture has the tools to help navigate and make cancer treatment much more precise. Our drug prediction technology improves the efficacy, compared to standard ’one size fits all’ treatments.

ABOUT US

Oncology Venture A/S

By combining our cutting edge prediction technology with cancer drugs, we offer precision treatment for patients with cancer.

Our patients have better chances of living longer and ultimately survive.

Our results are strong. We have data to prove this. And the prospect is profound.

The DRP Method

By combining cutting-edge science from the fields of genetics and oncology, Oncology Venture is the first to develop a Drug Response Predictor®, which can be combined with ultimately any cancer drug. 

Using this technology, our offset is treating the particular genetic characteristics of the tumor instead of the type of cancer, which has been the traditional treatment approach. Because cancers are different. Just like people.

Clinical up-date: Oncology Venture aims for approval of LiPlaCis®

Hoersholm, Denmark and Cambridge, MA, US, November 1, 2018 – Oncology Venture A/S, today announces its plans to aim for its first marketing approval of LiPlaCis® based on a single arm pivotal study. On the basis of current good data OV’s advisors and statisticians expect that a clinical study in 100-200 patients will be sufficient for a marketing approval of LiPlaCis® as a new treatment of breast cancer.

Oncology Venture A/S stock price (OV.ST)

Oncology Venture A/S is listed on Nasdaq First North in Stockholm with the ticker OV.ST

Oncology Venture has made great strides and our assessment is that via the progress we have made, we are playing in a new league.

Peter Buhl Jensen, CEO​